Cite
HARVARD Citation
De Ridder, F. et al. (2021). Mean HBsAg decline at week 24 of PEG‐IFN‐based treatment predicts subsequent rate of HBsAg clearance — suggesting a valuable endpoint for early development HBV trials. Journal of viral hepatitis. 28 (11), pp. 1563-1569. [Online].